Here’s what you should know.
1. LifeCell is a regenerative medicine company featuring several plastic surgery facing products.
2. Allergan is going to combine LifeCell’s products with its medical aesthetics, breast implants and tissue expanders to “create a world class aesthetic and regenerative medicine business.”
3. In addition to its commercial products, Allergan is acquiring LifeCell’s manufacturing capabilities and its research and development operation.
4. Allergan anticipates closing the deal during the first half of 2017.
5. Allergan’s stock opened on Dec. 20, 2016 at $192.38, dropped to $190 at the time of the announcement and closed at $191.06. As of 9 a.m. Dec. 21, 2016, the stock was trading at $194.11.
More articles on improving health:
Global disposable syringes market to surge to $9.9B by 2024: 4 points
Study: ’32k fewer patients would die every year if male physicians could achieve the same outcomes as female physicians’
3 GI-driven ASCs and facilities in the news — Dec. 20, 2016
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
